Fluoroquinolone Therapy for the Prevention of Multidrug-Resistant Tuberculosis in Contacts. A Cost-Effectiveness Analysis.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  American Journal of Respiratory and Critical Care Medicine

• Publication date

  2015-07-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1164/rccm.201501-0069OCPMID 25915791
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antituberculosis activity of ofloxacin (DL 8280) on experimental tuberculosis in mice.

  2015cited by this paper
• Tuberculosis morbidity in the U.S. Navy: its distribution and decline.

  2015cited by this paper
• A four-month gatifloxacin-containing regimen for treating tuberculosis.

  2015cited by this paper
• Treatment Practices, Outcomes, and Costs of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis, United States, 2005–2007

  2014cited by this paper
• Fluoroquinolone resistance in non-multidrug-resistant tuberculosis-a surveillance study in New South Wales, Australia, and a review of global resistance rates.

  2014cited by this paper
• A four-month gatifloxacin-containing regimen for treating tuberculosis.

  2014cited by this paper
• Treatment of latent tuberculosis infection: a network meta-analysis.

  2014cited by this paper
• Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012.

  2014cited by this paper
• Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.

  2014cited by this paper
• United States life tables, 2009.

  2014cited by this paper
• Risk of tuberculosis after recent exposure. A 10-year follow-up study of contacts in Amsterdam.

  2014cited by this paper
• Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis.

  2014cited by this paper
• What is the Cost of Diagnosis and Management of Drug Resistant Tuberculosis in South Africa?

  2013cited by this paper
• Cost-effectiveness of Xpert® MTB/RIF for diagnosing pulmonary tuberculosis in the United States.

  2013cited by this paper
• Community-Wide Isoniazid Preventive Therapy Drives Drug-Resistant Tuberculosis: A Model-Based Analysis

  2013cited by this paper
• Direct observation therapy-plus can prevent acquired resistance to fluoroquinolones among patients with multidrug-resistant tuberculosis in Taiwan.

  2013cited by this paper
• Adverse Events in Healthy Individuals and MDR-TB Contacts Treated with Anti-Tuberculosis Drugs Potentially Effective for Preventing Development of MDR-TB: A Systematic Review

  2013cited by this paper
• Preventive therapy for child contacts of multidrug-resistant tuberculosis: a prospective cohort study.

  2013cited by this paper
• Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes

  2012cited by this paper
• Strategies for Treating Latent Multiple-Drug Resistant Tuberculosis: A Decision Analysis

  2012cited by this paper
• Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients

  2012cited by this paper
• Current management options for latent tuberculosis: a review

  2012cited by this paper
• Three months of rifapentine and isoniazid for latent tuberculosis infection.

  2011cited by this paper
• Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model.

  2011cited by this paper
• Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study.

  2011cited by this paper
• 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.

  2011cited by this paper
• Safety Profile of the Fluoroquinolones

  2010cited by this paper
• Patient and family costs associated with tuberculosis, including multidrug-resistant tuberculosis, in Ecuador.

  2010cited by this paper
• Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis.

  2009cited by this paper
• Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure.

  2009cited by this paper
• Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial.

  2009cited by this paper
• Health state utilities in latent and active tuberculosis.

  2008cited by this paper
• Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia.

  2007cited by this paper
• Isoniazid Preventive Therapy and Risk for Resistant Tuberculosis

  2006cited by this paper
• Moxifloxacin, Ofloxacin, Sparfloxacin, and Ciprofloxacin against Mycobacterium tuberculosis: Evaluation of In Vitro and Pharmacodynamic Indices That Best Predict In Vivo Efficacy

  2006cited by this paper
• Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis.

  2006cited by this paper
• Fluoroquinolone resistance in patients with newly diagnosed tuberculosis.

  2003cited by this paper
• Isoniazid for preventing tuberculosis in non-HIV infected persons.

  1999cited by this paper
• Predictive value of contact investigation for identifying recent transmission of Mycobacterium tuberculosis.

  1998cited by this paper
• Recommendations of the Panel on Cost-effectiveness in Health and Medicine.

  1996cited by this paper
• In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR-3355).

  1995cited by this paper
• Tuberculosis in a cohort of Southeast Asian Refugees. A five-year surveillance study.

  1988cited by this paper
• Active tuberculosis after isoniazid chemoprophylaxis of Southeast Asian refugees.

  1986cited by this paper
• Frost revisited: the modern epidemiology of tuberculosis.

  1975cited by this paper
• Controlled chemoprophylaxis trials in tuberculosis. A general review.

  1970cited by this paper

• Evaluating the cost-effectiveness of levofloxacin therapy for household contacts of multidrug-resistant tuberculosis in Vietnam

  2025influential citation
• Preventing multidrug resistant tuberculosis: the dawn of a new era.

  2025cites this paper
• Economic Evaluation of Interventions to Reduce Antimicrobial Resistance: A Systematic Literature Review of Methods

  2025cites this paper
• Impacts of MDR/XDR-TB on the global tuberculosis epidemic: Challenges and opportunities

  2024cites this paper
• Waiting is no longer an option for household contacts of people with drug-resistant tuberculosis.

  2024cites this paper
• Tuberculosis Preventive Treatment in High TB-Burden Settings: A State-of-the-Art Review

  2024cites this paper
• Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis in Vietnam.

  2024cites this paper
• A systematic literature review of economic evaluation studies of interventions impacting antimicrobial resistance

  2023cites this paper
• Preventive Therapy for Contacts of Drug-Resistant Tuberculosis

  2022cites this paper
• The global impact of household contact management for children on multidrug-resistant and rifampicin-resistant tuberculosis cases, deaths, and health-system costs in 2019: a modelling study

  2022cites this paper
• Treatment of Rifampicin-Resistant Tuberculosis Disease and Infection in Children: Key Updates, Challenges and Opportunities

  2022cites this paper
• Population-wide active case finding and prevention for tuberculosis and leprosy elimination in Kiribati: the PEARL study protocol

  2022cites this paper
• Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine

  2021cites this paper
• Isoniazid or rifampicin preventive therapy with and without screening for subclinical TB: a modeling analysis

  2021cites this paper
• Multidrug-resistant tuberculosis in children and adolescents: current strategies for prevention and treatment

  2020cites this paper
• Finding New Ways to Combat Multidrug-Resistant Tuberculosis

  2020cites this paper
• Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (the VQUIN MDR trial): a protocol for a randomised controlled trial

  2020cites this paper
• Genotypic and phenotypic characterization of Mycobacterium tuberculosis resistance against fluoroquinolones in the northeast of Iran

  2020cites this paper
• The paradigm shift in the approach to management of latent tuberculosis infection in high tuberculosis burden countries

  2020cites this paper
• Preventive Therapy for Multidrug Resistant Latent Tuberculosis Infection: An Ethical Imperative with Ethical Barriers to Implementation?

  2020cites this paper
• Implications of a school outbreak of multidrug-resistant tuberculosis in Northern China

  2018cites this paper
• S0950268817003120jxx 584..588

  2018cites this paper
• Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study

  2018cites this paper
• Better than a pound of cure: preventing the development of multidrug-resistant tuberculosis.

  2018cites this paper
• Latent tuberculous infection in household contacts of multidrug-resistant and newly diagnosed tuberculosis.

  2017cites this paper
• Preventive therapy for latent tuberculosis infection-the promise and the challenges.

  2017cites this paper
• Neither genotyping nor contact tracing allow correct understanding of multidrug-resistant tuberculosis transmission

  2017cites this paper
• Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis

  2017cites this paper
• Overcoming challenges in the diagnosis, prevention, and treatment of pediatric drug-resistant tuberculosis

  2017cites this paper
• Treatment of Latent Tuberculosis Infection

  2017cites this paper
• Diagnosis and management of latent tuberculosis

  2016cites this paper
• PULMONARY, SLEEP, AND CRITICAL CARE UPDATE Update in Tuberculosis/Pulmonary Infections 2015

  2016cites this paper
• Assessing risk of tuberculosis in international travellers: progress and new challenges.

  2016cites this paper
• Update in Tuberculosis/Pulmonary Infections 2015.

  2016cites this paper
• Fluoroquinolone Preventive Therapy after Exposure to Multidrug-Resistant Tuberculosis? Hopes and Fears.

  2015cites this paper
• Update in Mycobacterium tuberculosis lung disease 2014.

  2015cites this paper